Cagrilintide
Long-acting amylin analog. Activates amylin and calcitonin receptors to suppress appetite via complementary pathway to GLP-1.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Novo Nordisk candidate. Combined with semaglutide as CagriSema — Phase 3 REDEFINE trials underway. Mechanism is complementary to GLP-1 (amylin signaling), so combined product targets stronger weight loss than semaglutide alone.
Not approved. Standalone use outside the CagriSema trial protocol is research-only. Identity verification of grey-market product is poor.
Disulfide bridge between Cys2-Cys7. C20 fatty acid conjugated at K1 via γGlu spacer.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
Cagrilintide — primary mechanism: long-acting amylin analog. activates amylin and calcitonin receptors to suppress appetite via complementary pathway to glp-1.
2 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 0.16-2.4 mg · weekly, subcutaneous (trial protocols)
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Investigational — Novo Nordisk Phase 3 (CagriSema)